Size | Price | Stock | Qty |
---|---|---|---|
1g |
|
||
5g |
|
||
10g |
|
||
50g |
|
||
100g |
|
||
Other Sizes |
|
Purity: ≥98%
Hydroxyurea (formerly known as NCI-c04831, NSC-32065; NCIc04831, NSC32065; Biosupressin; Carbamoyl oxime; Droxia; Hydroxycarbamide) is an approved antineoplastic drug that has been used for treating various cancers such as melanoma, sickle-cell disease and resistant chronic myelocytic leukemia. Through the inhibition of ribonucleoside diphosphate reductase, it inhibits DNA synthesis and induces cell death. A hydroxyurea may prevent HIV-1 from replicating. The 90% inhibitory concentration (IC90) of hydroxyurea for laboratory strains of HIV-1 in activated PBMC has been demonstrated by in vitro experiments to be 0.4 mM.
Targets |
HIV-1
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
The same patients' erythroid cells from their peripheral blood are treated with hydroxyurea in vitro one year after they stopped taking it orally for two years, starting at a dose of 5 mg/kg/day for five days a week and increasing to a maximum of 10 mg/kg/day. Thirteen β-Thal/HbE patients receive this treatment.Cells are treated in primary culture for 96 hours with 30 μM hydroxyurea.
|
|
Animal Protocol |
|
|
References |
Molecular Formula |
CH4N2O2
|
|
---|---|---|
Molecular Weight |
76.05
|
|
Exact Mass |
76.03
|
|
Elemental Analysis |
C, 15.79; H, 5.30; N, 36.83; O, 42.07
|
|
CAS # |
127-07-1
|
|
Related CAS # |
|
|
Appearance |
Solid powder
|
|
SMILES |
C(=O)(N)NO
|
|
InChi Key |
VSNHCAURESNICA-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
|
|
Chemical Name |
hydroxyurea
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (32.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (32.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (32.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (1314.92 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 13.1492 mL | 65.7462 mL | 131.4924 mL | |
5 mM | 2.6298 mL | 13.1492 mL | 26.2985 mL | |
10 mM | 1.3149 mL | 6.5746 mL | 13.1492 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01966731 | Active Recruiting |
Drug: Hydroxyurea | Sickle Cell Disease | Children's Hospital Medical Center, Cincinnati |
June 2014 | Phase 1 Phase 2 |
NCT04750707 | Active Recruiting |
Drug: Hydroxyurea | Sickle Cell Anemia in Children | Global Health Uganda LTD | March 9, 2021 | Phase 3 |
NCT04691323 | Active Recruiting |
Other: HU-Go app | Sickle Cell Disease Sickle B+ Thalassemia |
Ann & Robert H Lurie Children's Hospital of Chicago |
March 2, 2021 | Not Applicable |
NCT05485948 | Active Recruiting |
Drug: Ropeginterferon alfa-2b | Polycythemia Vera | PharmaEssentia | October 8, 2021 | Phase 2 |
NCT02493530 | Active Recruiting |
Drug: TGR-1202 Drug: ruxolitinib |
Myelofibrosis Polycythemia Vera |
Vanderbilt-Ingram Cancer Center | July 2015 | Phase 1 |